A Single-Center, Open-label, Randomized, Single Dose, Two-way Crossover Design to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules Under Fasting Conditions in Healthy Subjects
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs Pimicotinib (Primary)
- Indications Amyotrophic lateral sclerosis; Giant cell tumour of tendon sheath; Graft-versus-host disease; Osteosarcoma; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Abbisko Therapeutics
- 27 Dec 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 25 Nov 2024 New trial record